PT3651736T - Long-acting formulations - Google Patents

Long-acting formulations

Info

Publication number
PT3651736T
PT3651736T PT187398565T PT18739856T PT3651736T PT 3651736 T PT3651736 T PT 3651736T PT 187398565 T PT187398565 T PT 187398565T PT 18739856 T PT18739856 T PT 18739856T PT 3651736 T PT3651736 T PT 3651736T
Authority
PT
Portugal
Prior art keywords
long
acting formulations
formulations
acting
Prior art date
Application number
PT187398565T
Other languages
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3651736T publication Critical patent/PT3651736T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
PT187398565T 2018-04-16 2018-07-13 Long-acting formulations PT3651736T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18167463 2018-04-16

Publications (1)

Publication Number Publication Date
PT3651736T true PT3651736T (en) 2021-09-24

Family

ID=62002070

Family Applications (2)

Application Number Title Priority Date Filing Date
PT211785266T PT3943070T (en) 2018-04-16 2018-07-13 Long-acting formulations of bedaquiline
PT187398565T PT3651736T (en) 2018-04-16 2018-07-13 Long-acting formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT211785266T PT3943070T (en) 2018-04-16 2018-07-13 Long-acting formulations of bedaquiline

Country Status (2)

Country Link
EA (1) EA202090287A1 (en)
PT (2) PT3943070T (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355606A1 (en) * 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations

Also Published As

Publication number Publication date
EA202090287A1 (en) 2020-05-12
PT3943070T (en) 2024-02-06

Similar Documents

Publication Publication Date Title
IL273541A (en) Formulations
IL268697A (en) Formulations
IL269630A (en) Niraparib formulations
IL269621A (en) Niraparib formulations
IL273282A (en) Niraparib formulations
ZA202000215B (en) Long-acting formulations
GB201809976D0 (en) Novel formulations
GB201707189D0 (en) Novel formulations
GB201905477D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
GB201904338D0 (en) Fluorouracil-containing formulations
PT4045038T (en) New formulations
IL290356A (en) Larazotide formulations
GB201707187D0 (en) Novel formulations
IL284691A (en) Formulations
PT3651736T (en) Long-acting formulations
SG11202011823SA (en) Activator-nucleator formulations
GB201819028D0 (en) Butanol-based formulations
GB201911063D0 (en) Formulations
GB201905105D0 (en) Formulations
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations
GB201910092D0 (en) New formulations
GB201910093D0 (en) New formulations
GB201803201D0 (en) Formulations